CA2248784A1 - Derives de l'oxazolone et leur utilisation - Google Patents

Derives de l'oxazolone et leur utilisation Download PDF

Info

Publication number
CA2248784A1
CA2248784A1 CA002248784A CA2248784A CA2248784A1 CA 2248784 A1 CA2248784 A1 CA 2248784A1 CA 002248784 A CA002248784 A CA 002248784A CA 2248784 A CA2248784 A CA 2248784A CA 2248784 A1 CA2248784 A1 CA 2248784A1
Authority
CA
Canada
Prior art keywords
substituted
group
compound
groups
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248784A
Other languages
English (en)
Inventor
Masafumi Nakao
Hiroyuki Tawada
Keiji Kamiyama
Tsuneo Kanamaru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2248784A1 publication Critical patent/CA2248784A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne un agent anti-Helicobacter pylori, comprenant un composé de formule (I), dans laquelle A représente un noyau aromatique pouvant être substitué; R?1¿ et R?2¿, identiques ou différents, représentent un atome d'hydrogène ou un groupe hydrocarbure pouvant être substitué; R?3¿ et R?4¿, identiques ou différents, représentent un atome d'hydrogène, un groupe hydrocarbure pouvant être substitué, un groupe acyle, un groupe carbamoyle pouvant être substitué, ou un groupe carboxyle pouvant être estérifié; ou un sel dudit composé.
CA002248784A 1996-06-25 1997-06-24 Derives de l'oxazolone et leur utilisation Abandoned CA2248784A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP16485496 1996-06-25
JP8/164854 1996-06-25
JP2516297 1997-02-07
JP9/25162 1997-02-07
ZA978876A ZA978876B (en) 1996-06-25 1997-10-03 Oxazolone derivatives and their use

Publications (1)

Publication Number Publication Date
CA2248784A1 true CA2248784A1 (fr) 1997-12-31

Family

ID=27284916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248784A Abandoned CA2248784A1 (fr) 1996-06-25 1997-06-24 Derives de l'oxazolone et leur utilisation

Country Status (6)

Country Link
EP (1) EP0923577A2 (fr)
CN (1) CN1077892C (fr)
AU (1) AU3191397A (fr)
CA (1) CA2248784A1 (fr)
WO (1) WO1997049703A2 (fr)
ZA (1) ZA978876B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006697A1 (fr) * 1998-07-30 2000-02-10 Takeda Chemical Industries, Ltd. Procede de production d'indolemycine
DK1222922T3 (da) 1999-10-20 2007-12-03 Eisai R&D Man Co Ltd Fremgangsmåde til stabilisering af benzimidazolforbindelser
CA2550361C (fr) 2003-12-19 2014-04-29 Prabha Ibrahim Composes et methodes de developpement de modulateurs de ret
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
MA33028B1 (fr) 2009-04-03 2012-02-01 Plexxikon Inc Compositions et utilisations associees
CN102695417A (zh) 2009-11-06 2012-09-26 普莱希科公司 用于激酶调节的化合物和方法及其适应症
BR112013020041B1 (pt) 2011-02-07 2021-11-23 Plexxikon, Inc Compostos e composições para a modulação de quinases e uso dos mesmos
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR102491260B1 (ko) * 2019-12-26 2023-01-27 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
CN113480544B (zh) * 2021-07-09 2022-04-26 成都大学 一种炔基化咪唑并[1,5-a]吲哚化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US458385A (en) * 1891-08-25 Heater
GB862685A (en) * 1956-11-02 1961-03-15 Pfizer & Co C New antibiotic designated pa 155a
US3173923A (en) * 1961-04-13 1965-03-16 Pfizer & Co C 1-(3'-indolyl)-1-[5"-(2''-methylimino)-4''-ketooxazolidinyl] ethane and acid addition salts thereof
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US4584385A (en) * 1984-03-22 1986-04-22 Pfizer Inc. Antibacterial 2-amino-oxazolinones and process therefor
US5607932A (en) * 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones

Also Published As

Publication number Publication date
ZA978876B (en) 1999-06-30
AU3191397A (en) 1998-01-14
WO1997049703A3 (fr) 1998-02-26
CN1230958A (zh) 1999-10-06
CN1077892C (zh) 2002-01-16
WO1997049703A2 (fr) 1997-12-31
EP0923577A2 (fr) 1999-06-23

Similar Documents

Publication Publication Date Title
US6414003B1 (en) Oxazolone derivatives and their use as anti-helicobacter pylori agents
CA2248784A1 (fr) Derives de l'oxazolone et leur utilisation
US4556559A (en) Antibiotics
US4110165A (en) Process for the production of clavulanic acid
US4529720A (en) Antibiotic from Streptomyces clavulicerus
US4337199A (en) Antibiotic β-lactam compounds, production thereof, and their use as antimicrobial agent
US6051703A (en) Purified clavulanic acid and salts thereof
JPH02204499A (ja) ペプチド誘導体
US5294609A (en) DNA gyrase inhibitors and pharmaceutical preparations therefor
EP1319666B1 (fr) Composés antibacteriens
US4368203A (en) Antibiotics and derivatives thereof having β-lactamase inhibitory activity and production thereof
JPS6259107B2 (fr)
US4525353A (en) Antibiotics
US4060530A (en) Clavulanic acid amides
US4140764A (en) β-Lactamase inhibitors and process for their preparation
US4772595A (en) Synthetic virginiamycin M1 analogs
JP3305985B2 (ja) 抗ヘリコバクター・ピロリ剤
US4859690A (en) Therapeutic virginiamycin M1 analogs
US4762923A (en) Fermentation analogs of virginiamycin M1
US5137900A (en) Therapeutic virginiamycin M1 analogs
CA1279278C (fr) Analogues de fermentation de la virginiamycine m1
US5006466A (en) Fermentation analogs of virginiamycin M1
US4894370A (en) Compositions having fermentation analogs of virginiamycin M1 as active ingredient
US4942230A (en) Process for preparing synthetic virginiamycin M1 analogs
US4123540A (en) Isoclavulanic acid as an antibacterial and a β-lactamase inhibitor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead